About AC Immune S.A.
https://www.acimmune.comAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
CEO
Andrea Pfeifer
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:79.75M
Value:$292.69M
BVF INC/IL
Shares:19.82M
Value:$72.75M
BLACKROCK INC.
Shares:2.61M
Value:$9.57M
Summary
Showing Top 3 of 47
About AC Immune S.A.
https://www.acimmune.comAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $939K ▼ | $17.11M ▼ | $-15.86M ▲ | -1.69K% ▼ | $-0.16 ▲ | $-15.52M ▲ |
| Q2-2025 | $1.31M ▲ | $20.69M ▲ | $-21.19M ▼ | -1.62K% ▲ | $-0.21 ▼ | $-20.52M ▼ |
| Q1-2025 | $990K ▼ | $20.36M ▲ | $-19.03M ▼ | -1.92K% ▼ | $-0.19 ▼ | $-18.36M ▼ |
| Q4-2024 | $1.14M ▼ | $19.75M ▲ | $-15.8M ▼ | -1.39K% ▼ | $-0.14 ▼ | $-15.23M ▼ |
| Q3-2024 | $25.48M | $18.22M | $5.5M | 21.59% | $0.06 | $6.07M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $108.47M ▼ | $171.61M ▼ | $109.16M ▼ | $62.44M ▼ |
| Q2-2025 | $127.14M ▼ | $190.22M ▼ | $115.48M ▼ | $74.74M ▼ |
| Q1-2025 | $145.61M ▼ | $211.08M ▼ | $116.28M ▼ | $94.8M ▼ |
| Q4-2024 | $165.49M ▲ | $230.91M ▼ | $118.64M ▲ | $112.27M ▼ |
| Q3-2024 | $157.9M | $244.25M | $114.08M | $130.16M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-15.86M ▲ | $-18.34M ▼ | $20.63M ▼ | $-254K ▼ | $2.02M ▼ | $-18.4M ▼ |
| Q2-2025 | $-21.19M ▼ | $-15.6M ▲ | $23.88M ▲ | $-247K ▲ | $5.76M ▲ | $-15.97M ▲ |
| Q1-2025 | $-19.03M ▼ | $-18.82M ▼ | $3.03M ▲ | $-258K ▼ | $-16.32M ▼ | $-19.18M ▼ |
| Q4-2024 | $-15.8M ▼ | $5.93M ▲ | $-3.83M ▼ | $-197K ▼ | $3.86M ▲ | $5.84M ▲ |
| Q3-2024 | $5.5M | $-14.14M | $-2.09M | $-173K | $-19.15M | $-14.31M |
CEO
Andrea Pfeifer
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:79.75M
Value:$292.69M
BVF INC/IL
Shares:19.82M
Value:$72.75M
BLACKROCK INC.
Shares:2.61M
Value:$9.57M
Summary
Showing Top 3 of 47